Skip to main content

Advertisement

Table 1 Clinical characteristics for the study population

From: Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer

  Batch 1 (N = 132) Batch 2 (N = 296) Total (N = 428)
EOC status    
  Control 66 (50.0%) 148 (50.0%) 214 (50.0%)
  Case 66 (50.0%) 148 (50.0%) 214 (50.0%)
Age    
  Mean (SD) 60 (12) 63 (13) 62 (13)
  Median 61 65 64
  Q1, Q3 50, 69 54, 73 52, 72
  Range (33–82) (27–91) (27–91)
Year enrolled    
  1999–2002 18 (13.6%) 164 (55.4%) 182 (42.5%)
  2003 10 (7.6%) 36 (12.2%) 46 (10.7%)
  2004 41 (31.1%) 33 (11.1%) 74 (17.3%)
  2005 25 (18.9%) 23 (7.8%) 48 (11.2%)
  2006–2007 38 (28.8%) 40 (13.5%) 78 (18.2%)
Parity, number of births    
  Nulliparous 24 (18.2%) 42 (14.2%) 66 (15.4%)
  1-2,<=20 yrs 7 (5.3%) 14 (4.7%) 21 (4.9%)
  1-2,>20 yrs 31 (23.5%) 84 (28.4%) 115 (26.9%)
  3+,<=20 yrs 28 (21.2%) 47 (15.9%) 75 (17.5%)
  3+,>20 yrs 40 (30.3%) 95 (32.1%) 135 (31.5%)
Smoking status (current)    
  No 120 (90.9%) 259 (87.5%) 379 (88.6%)
  Yes 10 (7.6%) 19 (6.4%) 29 (6.8%)
State    
  Other 68 (51.5%) 120 (40.5%) 188 (43.9%)
  Minnesota 64 (48.5%) 176 (59.5%) 240 (56.1%)
Alcohol consumption    
  Never 32 (24.2%) 71 (24.0%) 103 (24.1%)
  Current 78 (59.1%) 152 (51.4%) 230 (53.7%)
  Former 18 (13.6%) 47 (15.9%) 65 (15.2%)
Histology    
  Serous 43 (65.2%) 98 (66.2%) 141 (65.9%)
  Mucinous 1 (1.5%) 4 (2.7%) 5 (2.3%)
  Endometrioid 16 (24.2%) 33 (22.3%) 49 (22.9%)
  Clear Cell 4 (6.1%) 9 (6.1%) 13 (6.1%)
  Other 2 (3.0%) 4 (2.7%) 6 (2.8%)
Grade    
  Grade 1 1 (1.6%) 9 (6.1%) 10 (4.7%)
  Grade 2 10 (15.6%) 21 (14.2%) 31 (14.6%)
  Grade 3 32 (50.0%) 79 (53.4%) 111 (52.4%)
  Grade 4 21 (32.8%) 39 (26.4%) 60 (28.3%)
Stage    
  Stage 1 11 (16.7%) 29 (19.6%) 40 (18.7%)
  Stage 2 3 (4.5%) 11 (7.4%) 14 (6.5%)
  Stage 3 43 (65.2%) 84 (56.8%) 127 (59.3%)
  Stage 4 9 (13.6%) 24 (16.2%) 33 (15.4%)